Darinaparsin (Darvias) Injection

Darinaparsin, marketed as Darvias by Solasia Pharma, is a mitochondria-targeted organoarsenic anticancer agent indicated for relapsed or refractory peripheral T-cell lymphoma (PTCL) in patients who have received prior systemic therapy. It is approved in Japan (PMDA), not currently by the US FDA.

Darinaparsin is an organic arsenic compound that accumulates in tumor cell mitochondria, disrupting mitochondrial function and inducing cancer cell death — a mechanism distinct from conventional chemotherapy.

• As an arsenic-based compound, cardiac monitoring (QT interval) and blood count monitoring are typically required during treatment.
• Infusion-related reactions may occur.
• Common side effects: fatigue, nausea, decreased blood counts (cytopenias), peripheral edema, electrolyte abnormalities.

What documents are required to import Darinaparsin to India?

Darinaparsin may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a registered oncologist
• Diagnostic/pathology report confirming relapsed or refractory PTCL
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription and an import permit, if applicable.

Is Darinaparsin available in India?

Darinaparsin is not commercially marketed in India. It can be legally accessed through the Named Patient Program (NPP), sourced from its Japan-approved supply chain.

Indian Pharma Network (IPN) can source Darinaparsin through Solasia Pharma’s Japan-approved distribution channel and facilitate supply to patients, doctors, and hospitals, subject to sourcing-country export rules.

For Darinaparsin cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• Japan: Approved by the PMDA — 2022. Not currently FDA-approved in the United States.

What is Darinaparsin used for?

Darinaparsin (Darvias) is used to treat relapsed or refractory peripheral T-cell lymphoma (PTCL).

Is Darinaparsin FDA-approved?

No — it is approved in Japan by the PMDA, not currently by the US FDA. It can still be imported into India via a Named Patient Program from its approved source market.

Who manufactures Darinaparsin?

Darinaparsin (Darvias) is developed and manufactured by Solasia Pharma K.K.

How much does Darinaparsin cost in India?

Cost depends on sourcing logistics from Japan, exchange rate, and quantity — contact IPN for a quote.